Year: 2025

Vital Energy Stockholders Approve Merger with Crescent Energy

Written by Customer Service on December 12, 2025. Posted in Mergers And Acquisitions.

TULSA, Okla., Dec. 12, 2025 (GLOBE NEWSWIRE) — Vital Energy, Inc. (NYSE: VTLE) (“Vital Energy” or the “Company”) today announced that, at a special meeting of Vital Energy stockholders held today, the stockholders of the Company approved the previously announced merger (the “Merger”) between Vital Energy and Crescent Energy Company (“Crescent”). Vital Energy will file the final vote results for its special meeting on a Form 8-K with the U.S. Securities and Exchange Commission (the “SEC”). The Merger is anticipated to close on December 15, 2025. “We appreciate the strong support from our stockholders, which underscores their confidence in the strategic combination of Vital Energy and Crescent,” stated Jason Pigott, President and CEO. “By joining forces,...

Edesa Biotech Reports Fiscal Year 2025 Results

Written by Customer Service on December 12, 2025. Posted in Earnings Releases And Operating Results.

TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) — Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2025 and provided an update on its business. During the year, the company initiated manufacturing activities for a Phase 2 study of Edesa’s dermatology drug candidate, EB06 (an anti-CXCL10 monoclonal antibody), in patients with moderate-to-severe nonsegmental vitiligo. Edesa anticipates that recruitment will begin by midyear 2026, subject to the completion of clinical-grade drug manufacturing and regulatory approvals. In its respiratory program, Edesa reported that a Phase 3 study of its monoclonal antibody, paridiprubart (EB05), met primary and secondary endpoints...

Ingredion Incorporated Declares Quarterly Dividend of $0.82 Per Share

Written by Customer Service on December 12, 2025. Posted in Dividend Reports And Estimates.

WESTCHESTER, Ill., Dec. 12, 2025 (GLOBE NEWSWIRE) — Ingredion Incorporated (NYSE: INGR), a leading global provider of ingredient solutions, announced today that its board of directors has declared a quarterly dividend of $0.82 per share on the Company’s common stock. The quarterly dividend will be payable on Jan. 20, 2026, to stockholders of record at the close of business on Jan. 2, 2026. For additional information about Ingredion Incorporated, including investor relations, financial updates, and upcoming announcements, visit https://ir.ingredionincorporated.com/. ABOUT THE COMPANY Ingredion Incorporated (NYSE: INGR) headquartered in the suburbs of Chicago, is a leading global ingredient solutions provider serving customers in more than 120 countries. With 2024 annual net sales of approximately $7.4 billion, the company turns...

Monolithic Power Systems Announces Fourth Quarter 2025 Dividend

Written by Customer Service on December 12, 2025. Posted in Dividend Reports And Estimates.

Schaffhausen, Switzerland, Dec. 12, 2025 (GLOBE NEWSWIRE) — Monolithic Power Systems, Inc. (Nasdaq: MPWR), a global company that provides high-performance, semiconductor-based power electronics solutions, announced today its fourth quarter dividend of $1.56 per share of common stock to all stockholders of record as of the close of business on December 31, 2025. The dividend will be paid on January 15, 2026. Safe Harbor Statement This news release includes “forward-looking statements” intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on our current expectations, estimates and projections about our business and industry, management’s beliefs, and certain assumptions made by us, all of which are subject to change....

Suntex Enterprises, Inc. Acquires JA Development & Construction, Establishing a National Residential, Commercial & Industrial Construction Platform

Written by Customer Service on December 12, 2025. Posted in Mergers And Acquisitions.

LAS VEGAS, Dec. 12, 2025 (GLOBE NEWSWIRE) — Suntex Enterprises, Inc. (OTC: SNTX) announced the acquisition of JA Development & Construction, a Texas-based construction firm with operating experience across residential, commercial, and industrial markets. The transaction brings a founder-built, operating business into the public markets and establishes a scalable construction platform designed for long-term growth and national expansion. JA Development & Construction was founded and led by Javier Leal, Chief Executive Officer of Suntex Enterprises, and has operated as a private company for the past five years. During that time, the company has delivered projects in collaboration with some of the world’s largest and most respected organizations, earning repeat business through execution, reliability, and disciplined operations. “JA...

Correction: Kaldalón hf.: Acquisition of the Property Portfolio of FÍ fasteignafélag

Written by Customer Service on December 12, 2025. Posted in Public Companies.

Kaldalón hf. (“Kaldalón”) and FÍ fasteignafélag slhf. (“FÍ fasteignafélag”) have signed Kaldalón’s purchase offer for all real estate assets owned by FÍ fasteignafélag. The property portfolio comprises 11 properties with a total floor area of approximately 25,200 square metres. All properties are located in the Greater Reykjavík area and include, among other things, a hotel, an embassy, a primary healthcare facility and office premises. Key assets within the portfolio include Hverfisgata 103, which houses a 100-room hotel; office premises at Borgartún 25; an embassy at Laufásvegur 31; retail and service premises at Bernhöftstorfa in central Reykjavík; a healthcare facility in Glæsibær, as well as other properties. Kaldalón’s purchase offer was submitted following a structured sale process and was assessed by the board of directors of FÍ...

Park Dental Partners Rings the Closing Bell on the Nasdaq in New York

Written by Customer Service on December 12, 2025. Posted in Public Companies.

Park Dental Partners Leadership at NasdaqPark Dental Partners CEO Pete Swenson (center), and Chief Clinical Officers, Dr. Chris Steel (left) and Dr. Alan Law (right) stand at Nasdaq podium before ringing closing bell.Celebrating the Closing BellPark Dental Partners leadership, doctors, team members and family celebrate ringing the closing bell at Nasdaq on Thursday, December 12.MINNEAPOLIS, Dec. 12, 2025 (GLOBE NEWSWIRE) — Park Dental Partners, Inc. (“Park Dental Partners” or the “Company”), today announced that on December 11, 2025, members of the Park Dental Partners team rang the closing bell on the Nasdaq Stock Market (“Nasdaq”) in New York to commemorate the successful completion of its recent public listing. The event was broadcast live, allowing potential stakeholders worldwide to join in the celebration. The...

Alpine Bank celebrates the enduring legacy of Founder J. Robert “Bob” Young

Written by Customer Service on December 12, 2025. Posted in Public Companies.

J. Robert “Bob” Young, founder and chairman of Alpine BankAlpine Banks of ColoradoGLENWOOD SPRINGS, Colo., Dec. 12, 2025 (GLOBE NEWSWIRE) — The Young family is saddened to announce the passing of their beloved father, life partner, grandfather and friend. Bob died peacefully on December 11, 2025, in Florida, surrounded by loved ones. J. Robert “Bob” Young, founder and chairman of Alpine Bank and its holding company, Alpine Banks of Colorado, leaves behind a remarkable legacy of leadership, generosity, and dedication to the people of Colorado. For more than 50 years, Young built Alpine Bank into one of Colorado’s most respected financial institutions, always guided by his belief in the power of caring for others. “Bob believed in people. He believed in doing what’s right, even when it wasn’t easy,” said Alpine Bank President...

Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial

Written by Customer Service on December 12, 2025. Posted in Public Companies.

First Patient Expected to be Dosed Next Week with Intranasal Foralumab PET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer’s Patient on Leqembi® (Lecanemab) Anti-Amyloid TherapyBOSTON, Dec. 12, 2025 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that enrolment has begun in its Phase 2 randomized, placebo-controlled early Alzheimer’s clinical trial and plans to dose the first patient next week. The Phase 2 clinical trial will evaluate intranasal foralumab both as monotherapy and in combination with an FDA approved anti-amyloid therapy, lecanemab or donanemab, in patients with early...

Kaldalón hf.: Acquisition of the Property Portfolio of FÍ fasteignafélag

Written by Customer Service on December 12, 2025. Posted in Public Companies.

Year: 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals